These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 17495622)

  • 1. Treatment and treatment trials in multiple sclerosis.
    Kieseier BC; Wiendl H; Hemmer B; Hartung HP
    Curr Opin Neurol; 2007 Jun; 20(3):286-93. PubMed ID: 17495622
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice.
    Costello F; Stüve O; Weber MS; Zamvil SS; Frohman E
    Curr Opin Neurol; 2007 Jun; 20(3):281-5. PubMed ID: 17495621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple sclerosis: new treatment trials and emerging therapeutic targets.
    DeAngelis T; Lublin F
    Curr Opin Neurol; 2008 Jun; 21(3):261-71. PubMed ID: 18451708
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disease-modifying drugs for the early treatment of multiple sclerosis.
    Flachenecker P
    Expert Rev Neurother; 2004 May; 4(3):455-63. PubMed ID: 15853542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunopathogenesis and immunotherapeutic approaches in multiple sclerosis.
    Lim ET; Giovannoni G
    Expert Rev Neurother; 2005 May; 5(3):379-90. PubMed ID: 15938671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews.
    Clerico M; Rivoiro C; Contessa G; Viglietti D; Durelli L
    Clin Neurol Neurosurg; 2008 Nov; 110(9):878-85. PubMed ID: 18164542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Advances in the treatment of multiple sclerosis?].
    Tackenberg B; Himmerich H; Wellek A; Oertel WH; Sommer N
    MMW Fortschr Med; 2007 May; 149 Suppl 2():51-5. PubMed ID: 17724968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toward the development of rational therapies in multiple sclerosis: what is on the horizon?
    Hemmer B; Hartung HP
    Ann Neurol; 2007 Oct; 62(4):314-26. PubMed ID: 17969020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials.
    Wiendl H; Hohlfeld R
    BioDrugs; 2002; 16(3):183-200. PubMed ID: 12102646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of multiple sclerosis: current trials and future options.
    Noseworthy JH
    Curr Opin Neurol; 2003 Jun; 16(3):289-97. PubMed ID: 12858064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials.
    Bates D
    Neurology; 2011 Jan; 76(1 Suppl 1):S14-25. PubMed ID: 21205678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Getting specific: monoclonal antibodies in multiple sclerosis.
    Lutterotti A; Martin R
    Lancet Neurol; 2008 Jun; 7(6):538-47. PubMed ID: 18485317
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Pharmacological treatment of multiple sclerosis].
    Myhr KM
    Tidsskr Nor Laegeforen; 2010 Mar; 130(5):490-2. PubMed ID: 20224616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current disease-modifying treatment of multiple sclerosis.
    Derwenskus J
    Mt Sinai J Med; 2011; 78(2):161-75. PubMed ID: 21425262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Current immunotherapy of multiple sclerosis].
    Paul F; Ruprecht K
    Nervenarzt; 2015 Aug; 86(8):1031-42; quiz 1043-4. PubMed ID: 26253589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunomodulatory therapy in multiple sclerosis].
    Csépány T; Bereczki D
    Ideggyogy Sz; 2004 Nov; 57(11-12):401-16. PubMed ID: 15662768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Confounders in natural history of interferon-beta-treated relapsing multiple sclerosis.
    Gout O
    Ann Neurol; 2008 Jan; 63(1):126; author reply 126-7. PubMed ID: 17702028
    [No Abstract]   [Full Text] [Related]  

  • 18. Lessons from randomised direct comparative trials.
    Achiron A; Fredrikson S
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S19-24. PubMed ID: 19200860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current immunotherapy of multiple sclerosis and future challenges: relevance of immune-mediated repair.
    Carrithers MD
    Curr Pharm Biotechnol; 2012 Jun; 13(8):1409-17. PubMed ID: 22339217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interferon-beta treatment and the natural history of relapsing-remitting multiple sclerosis.
    Koch M; Mostert J; De Keyser J; Tremlett H; Filippini G
    Ann Neurol; 2008 Jan; 63(1):125-6; author reply 126-7. PubMed ID: 17702024
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.